Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06089616 · ClinicalTrials.gov registry record
A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
A clinical trial of Fibrodysplasia Ossificans Progressiva, sponsored by Ipsen.
- Recruiting
- Registry status
- 100
- Enrollment target
- 5
- Study locations
NCT06089616 is a study of Fibrodysplasia Ossificans Progressiva that is actively recruiting participants, run by Ipsen. The registered enrollment target is 100 participants, above the 79-participant average among 4 other Fibrodysplasia Ossificans Progressiva trials with a reported enrollment target (27% higher). The trial reports 5 study locations across 3 states.
The verdict
NCT06089616, a study of Fibrodysplasia Ossificans Progressiva, is actively recruiting participants, sponsored by Ipsen.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 5
- Study locations
Study Summary
The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)). HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups). This registry study will take place in countries where the treatment, known as palovarotene, has been approved for use. Participants will either be treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) or untreated with palovarotene. The main aim of this registry study will be to collect and assess real-world safety data on children and adult participants with FOP treated with palovarotene. This registry study will also describe the effectiveness of palovarotene in exposed participants, including the effect on everyday activities and physical performance. In addition, this registry study aims to descriptively compare key safety outcomes (i.e. flare-up episodes, growth outcomes, and bone fractures) between participants exposed and unexposed to palovarotene.
Conditions Studied
Study Locations (5)
Other
- Edmonton Clinic Health Academy (ECHA)- University of Alberta - Edmonton
- Bone Research and Education Centre - Oakville
- University Health Network (UHN) - Toronto General - Toronto
California
- The Regents of the University of California - San Francisco
Pennsylvania
- The Trustees of the University of Pennsylvania, Office of Clinical Research-Legal Services, Perelman School of Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-12-05 |
| Est. Completion | 2035-12-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06089616
The ClinicalTrials.gov registry entry for NCT06089616 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 79-participant average among 4 other Fibrodysplasia Ossificans Progressiva trials with a reported enrollment target (27% higher). The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fibrodysplasia Ossificans Progressiva appearing as the primary indexed condition, and to 0 interventions.
NCT06089616 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06089616 about?
NCT06089616 is a clinical study titled "A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)". The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)). HO is often preceded by painf...
What is the current status of trial NCT06089616?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-12-05. Estimated completion is 2035-12-05.
What conditions does trial NCT06089616 study?
This clinical trial studies the following conditions: Fibrodysplasia Ossificans Progressiva.
Who is sponsoring clinical trial NCT06089616?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06089616 being conducted?
This trial has 5 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibrodysplasia Ossificans Progressiva
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
ACTIVE NOT RECRUITING · Phase 2
-
Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.